In a report released yesterday, Kallum Titchmarsh from Morgan Stanley maintained a Hold rating on Personalis, with a price target of $11.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kallum Titchmarsh has given his Hold rating due to a combination of factors tied to Personalis’s recent performance and outlook. The company ended 2025 with solid cash reserves and secured key Medicare coverage decisions in breast and early-stage lung cancer, which should support growing clinical test volumes and expand its presence in the MRD market.
However, revenue guidance for 2026 falls short of consensus expectations, and the business mix is shifting away from higher prior contributions like enterprise and population sequencing. Management also anticipates lower gross margins and a wider net loss in 2026 as they invest heavily to drive clinical adoption, creating a less favorable near-term risk‑reward profile that justifies a neutral, or Hold, stance.
In another report released on February 27, TipRanks – Anthropic also reiterated a Hold rating on the stock with a $8.50 price target.
PSNL’s price has also changed dramatically for the past six months – from $5.090 to $8.930, which is a 75.44% increase.